The FDA dealt the biotech and its big partner a huge setback.
News & Analysis: Galapagos
GLPG earnings call for the period ending June 30, 2020.
Binary events could send shares of these stocks screaming higher, or lower, soon.
Is an industry leader in treating cystic fibrosis or a company with a potential miracle drug the better buy for investors?
In a phase 2b/3 study in ulcerative colitis, the drug candidate met its goals, but with results that didn't appear better than those of a potential competitor.
GLPG earnings call for the period ending March 31, 2020.
Investors may want to own this biotech before its lead drug gets approved.
Immunology drug filgotinib appears to have great prospects. But are those prospects already baked into Galapagos' share price?
GLPG earnings call for the period ending December 31, 2019.
One of these biotechs dominates the treatment of cystic fibrosis. The other doesn't have a single FDA-approved drug -- yet.